ClinicalTrials.gg
CompletedNCT02764125COMPOCUpdated Apr 5, 2018

Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC)

A Phase 2 interventional study of Stalevo and levodopa MR in Parkinson's Disease, sponsored by Orion Corporation, Orion Pharma. Completed at 4 sites in 4 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2018-04-05.

Sponsored by Orion Corporation, Orion Pharma · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Parkinson Disease by Orion Corporation, Orion Pharma — none open to participants now, none under way, none of them phase 3. Parkinson Disease · Orion Corporation, Orion Pharma.

Enrollment
5th of 11
84 · median 27
Started
2016
the only one that year
Phase 2
4 of 11
none open now
Registered
10th of 11
by date

Among the 11 studies in Parkinson Disease by Orion Corporation, Orion Pharma, this one is the 5th largest by enrollment, is the only one that started in 2016, is one of 4 in phase 2, and was the 10th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

None of the 11 studies in Parkinson Disease by Orion Corporation, Orion Pharma is open now. The open studies under Parkinson Disease, anywhere →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Parkinson Disease by Orion Corporation, Orion Pharma as a file.
02

Study summary

This will be a randomised, crossover, double-blind, double-dummy, active-controlled, multicentre, phase II proof-of-concept study in Parkinson's Disease (PD) patients with end-of-dose wearing-off (motor fluctuations).

Read the detailed description

This will be a randomised, crossover, double-blind, double-dummy, active-controlled, multicentre, phase II proof-of-concept study in PD patients with end-of-dose wearing-off (motor fluctuations).

In a 2-period crossover design the subjects will receive ODM-104/levodopa/ carbidopa or Stalevo during the different study periods in a randomised order. There will be a screening period, 2 treatment periods and a post-treatment period, altogether 7 scheduled visits: a screening visit, a baseline visit, 4 visits during the treatment periods (i.e. 2 visits/each period), and an end-of-study visit. Unscheduled visits may be performed during the first 2 weeks of each treatment period, if there is a need to adjust the levodopa strength. The total study duration will be 10-15 weeks for each subject.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

Keywords

  • Parkinson's Disease
  • Wearing-off
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written (IC) obtained.
  • Male or female patients with idiopathic PD according to the UK brain bank criteria with end-of-dose wearing-off (motor fluctuations).
  • Hoehn and Yahr stage 2-4 performed during the ON-state.
  • At least 2 hours of OFF-time on each day (measured by the ON/OFF diary) on 3 consecutive days at the end of the screening period just before the baseline visit (visit 1).
  • Treatment with 4-8 daily doses of levodopa/AADC inhibitor, either combined with entacapone (levodopa/AADC inhibitor combined with Comtess/Comtan or as Stalevo) or without entacapone, with a total daily levodopa dose from > 400 mg to ≤ 1200 mg with entacapone, or from > 400 mg to ≤ 1400 mg without entacapone. One evening dose of controlled release formulation, 1 morning dose of soluble levodopa/AADC inhibitor, or both, as needed are allowed.
  • Unchanged levodopa/AADC inhibitor with or without entacapone, and other antiparkinsonian medication (dopamine agonists, monoamine oxidase [MAO] B inhibitor, amantadine and/or anticholinergics with doses recommended by the manufacturer), if any, for at least 4 weeks before the screening visit.
  • Age of 30 years or above.

Exclusion criteria

Exclusion Criteria:

  • Secondary or atypical Parkinsonism.
  • Current use of tolcapone or opicapone (within 4 weeks before the screening visit).
  • Previous tolerability problems with entacapone, tolcapone or opicapone.
  • Concomitant treatment with apomorphine, MAO-A inhibitors or non-selective MAO inhibitors (within 4 weeks before the screening visit).
  • Concomitant treatment with drugs having antidopaminergic action including alpha-methyldopa, reserpine and antipsychotic drugs (also D2 receptor blocking antiemetics except domperidone). As an exception to prohibit use of antipsychotic drugs, 1 evening dose of an atypical antipsychotic is allowed.
  • Use of concomitant medicine which is predominantly metabolised by and which has a narrow therapeutic window such as ergot alkaloids, carbamazepine, cyclosporin, macrolides (sirolimus and tacrolimus), quinidine or fentanyl.
  • Current use of warfarin (within 4 weeks before the screening visit).
  • Inability to refrain from use of any iron preparations during the study.
  • Disabling dyskinesias.
  • Problematic hallucinations within 3 months before the screening visit.
  • Symptomatic orthostatic hypotension.
  • Current dementia ( [MMSE] score \< 26).
  • Problematic impulse control disorders (ICDs), such as pathological gambling, hypersexuality or compulsive shopping within 6 months before the screening visit.
  • History of neuroleptic malignant syndrome (NMS), non-traumatic rhabdomyolysis, or both.
  • Any neurosurgical intervention for the treatment of PD, including deep brain stimulation (DBS).
  • Narrow-angle glaucoma or pheochromocytoma.
  • Any active malignant cancer.
  • cardiovascular (e.g. ischaemic heart disease, ventricular or supraventricular arrhythmias), pulmonary, GI (e.g. inflammatory bowel disease), hepatic, renal, neurological or psychiatric disorder or any other major concurrent illness that in the opinion of the investigator would interfere with the interpretation of the study results or constitute a health risk for the subject if he/she takes part into the study.
  • or aspartate aminotransferase > 1.25 x (ULN) at screening.
  • Any other abnormal value of laboratory, vital signs or (such as prolongation ≥ 450 ms) that may in the opinion of the investigator interfere with the interpretation of the study results or cause health risk for the subject if he/she takes part into the study.
  • Female patients of (i.e. menstruating or less than 2 years ).
  • Patients with pre-planned surgery requiring hospitalisation during the study.
  • Known to active substances or to any of the of the study treatments.
  • Blood donation or loss of significant amount of blood within 60 days before screening visit.
  • Participation in a drug study within 60 days before the first treatment period.
  • Any other condition that in the opinion of the investigator would interfere with the interpretation of the study results or constitute a health risk for the subject if he/she takes part into the study.
  • Failure to demonstrate acceptable/appropriate use of the ON/OFF diary despite adequate training during the screening visit.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
84 participants (actual)

Study arms

  • Active comparator
    Stalevo

    levodopa/carbidopa/entacapone

    Drug: Stalevo

  • Experimental
    levodopa MR

    Levodopa MR/carbidopa/ODM-104

    Drug: levodopa MR

Interventions

  • levodopa/carbidopa/entacapone

    Also known as: levodopa/carbidopa/entacapone

  • Druglevodopa MR

    levodopa MR/carbidopa/ODM-104

    Also known as: levodopa MR/carbidopa/ODM-104

06

What researchers measure

Primary outcomes

  1. Duration of daily OFF-time (measured by Hauser ON/OFF-diary)

    OFF-time (time when the patient does not experience a positive response to medication between the study drug intake) measured from the Hauser ON/OFF-diary that patient has filled in (24 hour clock) for 3 days prior to baseline visit and at the end of both treatment periods.

    Time frame: 3 consecutive days in the end of both periods compared to 3 consecutive days prior the baseline visit.

Secondary outcomes

  1. Switching patients from their regular levodopa treatment to planned new treatment.

    To explore how to switch patients on levodopa/aromatic amino acid decarboxylase (AADC) inhibitor or levodopa/AADC inhibitor + entacapone directly to ODM-104 in combination with MR levodopa and carbidopa by evaluating how much adjustments to levodopa strengths need to be done and if there is difference between the two treatment groups.

    Time frame: two 4 weeks study periods

  2. Determination of sample size

    To determine the effect size for phase III planning if the difference between the two study treatment groups with this amount of patients can be shown.

    Time frame: two 4 weeks study periods

  3. To show adequate Parkinson's Disease symptom control with the new treatment

    To study levodopa daily dose and dosing frequency of the combination to see if Parkinson's disease symptoms are adequately controlled with study treatment.

    Time frame: two 4 weeks study periods

07

Study locations

4 sites
  • Clinical Research Services Turku CRST
    Turku, 20520, Finland
  • Study Coordinating Investigator
    Harleshausen, Kassel 34128, Germany
  • Semmelweis Egyetem Neurológiai Klinika
    Budapest, 1083, Hungary
  • Investigator
    Riga, LV1012, Latvia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in Mar 2018, 23 months.

Of 97 industry-sponsored phase 2 interventional studies under Parkinson Disease, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 33. This study's 23 months is above that.

Counting every sponsor, half of 203 studies reached it within 28 months; a quarter within 16 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2016
First posted
May 6, 2016
StartActual
Apr 8, 2016
Primary completionActual
Mar 27, 2018
CompletionActual
Mar 27, 2018
Last update
Apr 5, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02764125
Responsible party
Sponsor
First posted
May 6, 2016
Start date
Apr 8, 2016
Primary completion
Mar 27, 2018
Completion
Mar 27, 2018
Last update
Apr 5, 2018

Study contacts

Aila Holopainen, MSc
study director · Orion Corporation, Orion Pharma, Development

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion